Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 486, Issue 1, Pages 67-74Publisher
ELSEVIER
DOI: 10.1016/j.ejphar.2003.12.005
Keywords
Ca2+-sensitization; phosphodiesterase inhibition; phosphodiesterase subtype; positive inotropy; levosimendan; OR-1896
Categories
Ask authors/readers for more resources
The concentration dependences of the Ca2+-sensitizing and the phosphodiesterase-inhibitory effects of levosimendan (the ( -) enantiomer of {[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono}propanedinitrile) and its active metabolite, OR-1896 (the (-) enantiomer of N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl] acetamide), were compared with their positive inotropic effects to reveal their mechanisms of action in guinea pig hearts. In Langendorff-perfused hearts, left ventricular +dP/dt(max) increased by 26 +/- 4% and 25 +/- 3% (mean +/- S.E.M.), with EC50 values of 15 +/- 2 and 25 +/- 1 nM for levosimendan and OR- 1896, respectively. In permeabilized myocyte-sized preparations, levosimendan and OR- 1896 both increased isometric force production via Ca2+ sensitization (at pCa 6.2), by 51 +/- 7% and 52 +/- 6%, with EC50 values of 8 +/- 1 and 36 +/- 7 nM (P < 0.05), respectively. Thus, the two molecules could be defined as Ca2+ sensitizers and positive inotropes with very similar concentration dependences. However, major differences appeared when the phosphodiesterase-inhibitory effects of levosimendan and OR-1896 were probed on the two phosphodiesterase isoforms (phosphodiesterases III and IV) dominant in the left ventricular cardiac tissue. Levosimendan was a 40-fold more potent and a 3-fold more selective phosphodiesterase III inhibitor (IC50 for phosphodiesterase III=2.5 nM, and IC50 for phosphodiesterase IV=25 muM, selectivity factor approximate to 10000) than OR-1896 QC(50) for phosphodiesterase III=94 nM, and IC50 for phosphodiesterase IV=286 muM, selectivity factor approximate to 3000). Hence, our data support the hypothesis that levosimendan and OR-1896 both exert positive inotropy via a Ca2+ -sensitizing mechanism and not via simultaneous inhibition of the phosphodiesterases III and IV isozymes in the myocardium. at their maximal free plasma concentrations. (C) 2004 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available